Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by MHemorrhageon Sep 24, 2020 2:31pm
128 Views
Post# 31612561

RE:Scientific Panel - 6 Docs

RE:Scientific Panel - 6 DocsNice digging. Looks like the Brit is Dr. Graeme Moyle, Associate Director of HIV Research at Chelsea and Westminster Hospital. 369 publications or cites, largely devoted to HIV and lipodystrophy. He's on the editorial board for HIV & Virology News. He was/is a speaker and advisor to BMS, Gilead Science, and Merck. He's on the board of Tobira Therapeutics.

Wino115 wrote: Just for reference, I was trying to put together the Scientific Panel that was part of the decision and found something on everyone but the UK guy.  Looks like it's fairly evenly split with NASH specialists and NASH HIV specialists. I put a few backgrounders on those we don't already know. Marsolais mentioned them all on the call.  Couldn't quite make out the last name of the London doctor.  Pretty impressive though and I would guess some may be in the clinical trials and probably helped design the proposed Trial.  Decent EU component which is good for EMA side. Frankly, the German and French doctors seem very impressive insofar as publications and running NASH or HIV organizations. Seems they're all involved in NASH trials so I would guess they'll be leads for THTX.  Glad to see all the brainpower used to make their decision.

1. Grinspoon - MGH
2. Loomba -Univ Cal San Diego  NASH expert


3. Jennifer Price - Univ Cal San Fran HIV & Liver background

Dr. Jennifer Cohen Price is a gastroenterologist and hepatologist, an expert in liver disease. She specializes in caring for patients awaiting liver transplants.

In her research, Price addresses liver disease in HIV-positive patients. She also studies viral hepatitis and nonalcoholic fatty liver disease.

Price earned her medical degree at Johns Hopkins School of Medicine and continued her medical training there, completing a residency, a fellowship in gastroenterology and hepatology, and a fellowship in transplant hepatology. She earned her doctorate degree in clinical investigation at Johns Hopkins School of Public Health.

Price is a fellow of the American College of Physicians. She is a member of the American College of Gastroenterology, American Gastroenterological Association and American Association for the Study of Liver Diseases.


4. Vlad Ratziu -Professor of Hepatology at Sorbonne Universit and Piti-Salptrire Hospital

Vlad Ratziu, MD, PhD, is a Professor of Hepatology at Sorbonne University and Piti-Salptrire Hospital in Paris, France. His main research interests are in the field of NAFLD; the mechanisms, risk factors, and progression of liver fibrosis in viral and metabolic diseases; and the treatment of viral hepatitis and hepatocellular carcinoma. He has participated in early, mid, and late-stage trials of NASH and has published more than 260 articles in prominent journals.

Prof. Ratziu coordinated the Fatty Liver Inhibition of Progression (FLIP) consortium, which sought to study both the mechanisms of liver disease progression in NAFLD and potential interventions, drawing on the largest cohort of NAFLD patients in Europe. He is co-editor for the Journal of Hepatology.

5. Jrgen Rockstroh, MD   Univ of Bonn
is Professor of Medicine and Head of the HIV Outpatient Clinic at the University of Bonn in Germany. He earned a Doctor of Medicine degree from the Rheinische Friedrich-Wilhelms University of Bonn, and completed his residency in the Department of Medicine also at the University of Bonn. His department treats the world’s largest cohort of HIV-infected hem
ophiliacs.

 In addition to his clinical practice, Dr Rockstroh is involved in HIV research on: antiretroviral therapy, including new drug classes; the course of HIV disease in haemophiliacs; and HIV and hepatitis co-infection. He has been an investigator in multiple clinical trials of antiretroviral agents and treatments for HIV and hepatitis co-infection.

From 2007-2011 he was elected as the president of the German AIDS Society. He is also since 2009 a member of the executive committee of the European AIDS Clinical Society (EACS) and since 2011 member of the governing council of the International AIDS Society. He currently chairs the hepatitis research activities in NEAT and EuroSIDA. He is also the chair of the National German AIDS Advisory Panel since 2011 and the EACS coinfection guidelines since 2008. In 2015 Professor Rockstroh was elected chair of HIV in Europe.

The German Society for Infectious Diseases awarded Dr Rockstroh and his co-authors the prize in clinical infectious diseases in 2002, and the national AIDS research prize in 2005. Dr Rockstroh has authored or co-authored over 400 publications in peer-reviewed journals, and over 70 book chapters.

6. Graham ??  Chelsea & Westminster Hospital...couldn't find him.



Bullboard Posts